Hearing covers HIPAA misinterpretation

| | Health Exec | Cybersecurity

A misunderstanding or over-interpretation of HIPAA by healthcare providers is preventing vital health information from being shared with family and caregivers, according to an April 26 Congressional hearing on the law.

Rep. Tim Murphy, PhD, (R-Pa.) noted instances when doctors did not share concerns about patients with the family, citing the 1996 HIPAA law as the reason, and the patients later took their own life. Murphy, a clinical psychologist and chair of the House Energy and Commerce Oversight and Investigations subcommittee, expressed worry that actions like this could hinder patient care and might fail to prevent public health tragedies. For example, patients with mental illness could be at risk of killing themselves or others, or patients with chronic conditions could miss out on obtaining the care they need.

Does HIPAA help or hinder patient care and patient safety

Related Content

FBI seeking extradition of Israeli prisoner accused of $500M in ransomware attacks
Data breach at chain of clinics impacts 450K patients
Nebraska becomes first state to sue Change Healthcare over data breach
Christmas ransomware exposed over 300K patient records to dark web
Cryo-frozen tissue manufacturer suffers cyberattack
First surgical device of its kind granted key FDA exemption

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.